Postoperative PSA and PSA Velocity Identify Presence of Prostate Cancer After Various Surgical Interventions for Benign Prostatic Hyperplasia

Urology

Volumn 74, Issue 1, 2009, Pages 177-183

  Helfand, Brian T ^a   Anderson, Christopher B ^a   Fought, Angela ^a   Kim, Dae Y ^a   Vyas, Ashish ^a   McVary, Kevin T ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; STEROID 5ALPHA REDUCTASE INHIBITOR;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CONTROLLED STUDY; HISTOLOGY; HOLMIUM LASER; HUMAN; HUMAN TISSUE; INCIDENTAL FINDING; LASER SURGERY; MAJOR CLINICAL STUDY; MALE; POSTOPERATIVE PERIOD; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROSTATECTOMY; RETROSPECTIVE STUDY; TRANSURETHRAL RESECTION;

AGED; HUMANS; MALE; MIDDLE AGED; POSTOPERATIVE CARE; PREDICTIVE VALUE OF TESTS; PREOPERATIVE CARE; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES;

EID: 67649363487     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2008.10.062     Document Type: Article

References (21)

1. Marks L.S., Dorey F.J., Rhodes T., et al. Serum prostate specific antigen levels after transurethral resection of prostate: a longitudinal characterization in men with benign prostatic hyperplasia. J Urol 156 (1996) 1035-1039
2. Roehrborn C.G., Boyle P., Gould A.L., et al. Serum prostate-specific antigen as a predictor of prostate volume in men with benign prostatic hyperplasia. Urology 53 (1999) 581-589
3. Mochtar C.A., Kiemeney L.A., Laguna M.P., et al. PSA velocity in conservatively managed BPH: can it predict the need for BPH-related invasive therapy?. Prostate 66 (2006) 1407-1412
4. Shen S., Lepor H., Yaffee R., et al. Ultrasensitive serum prostate specific antigen nadir accurately predicts the risk of early relapse after radical prostatectomy. J Urol 173 (2005) 777-780
5. Stewart A.J., Scher H.I., Chen M.H., et al. Prostate-specific antigen nadir and cancer-specific mortality following hormonal therapy for prostate-specific antigen failure. J Clin Oncol 23 (2005) 6556-6560
6. Chung C.S., Chen M.H., Cullen J., et al. Time to prostate-specific antigen nadir after androgen suppression therapy for postoperative or postradiation PSA failure and risk of prostate cancer-specific mortality. Urology 71 (2008) 136-140
7. Tinmouth W.W., Habib E., Kim S.C., et al. Change in serum prostate specific antigen concentration after holmium laser enucleation of the prostate: a marker for completeness of adenoma resection?. J Endourol 19 (2005) 550-554
8. Gupta N., Kumar R., et al. Comparison of standard transurethral resection, transurethral vapour resection and holmium laser enucleation of the prostate for managing benign prostatic hyperplasia of >40 g. Sivaramakrishna [sic]. BJU Int 97 (2006) 85-89
9. Matsuoka K., Iida S., Tomiyasu K., et al. Transurethral holmium laser resection of the prostate. J Urol 163 (2000) 515-518
10. Boyle P., Robertson C., Vaughan E.D., et al. A meta-analysis of trials of transurethral needle ablation for treating symptomatic benign prostatic hyperplasia. BJU Int 94 (2004) 83-88
11. Djavan B., and Marberger M. Transurethral microwave thermotherapy: an alternative to medical management in patients with benign prostatic hyperplasia?. J Endourol 14 (2000) 661-669
12. Helfand B., Mouli S., Dedhia R., et al. Management of lower urinary tract symptoms secondary to benign prostatic hyperplasia with open prostatectomy: results of a contemporary series. J Urol 176 (2006) 2557-2561
13. Zlotta A.R., Giannakopoulos X., Maehlum O., et al. Long-term evaluation of transurethral needle ablation of the prostate (TUNA) for treatment of symptomatic benign prostatic hyperplasia: clinical outcome up to five years from three centers. Eur Urol 44 (2003) 89-93
14. Guess H.A., Gormley G.J., Stoner E., et al. The effect of finasteride on prostate specific antigen: review of available data. J Urol 155 (1996) 3-9
15. Thompson I.M., Pauler Ankerst D., Chi C., et al. Prediction of prostate cancer for patients receiving finasteride: results from the prostate cancer prevention trial. J Clin Oncol 25 (2007) 3076-3081
16. Etzioni R.D., Howlader N., Shaw P.A., et al. Long-term effects of finasteride on prostate specific antigen levels: results from the prostate cancer prevention trial. J Urol 174 (2005) 877-881
17. Carter H.B., and Pearson J.D. PSA velocity for the diagnosis of early prostate cancer. a new concept. Urol Clin North Am 20 (1993) 665-670
18. Connolly D., Black A., Murray L.J., et al. Methods of calculating prostate-specific antigen velocity. Eur Urol 52 (2007) 1044-1050
19. Orihuela E., Kocurek J.N., and Warren M.M. Value of prostatic cancer screening in patients treated for benign prostatic hyperplasia with medical or minimally invasive modalities. Arch Esp Urol 50 (1997) 821-824
20. Carter H.B., Morrell C.H., Pearson J.D., et al. Estimation of prostatic growth using serial prostate-specific antigen measurements in men with and without prostate disease. Cancer Res 52 (1992) 3323-3328
21. Carter H.B., Ferrucci L., Kettermann A., et al. Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability. J Natl Cancer Inst 98 (2006) 1521-1527